We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

For a few dollars more

14 January 2011 By Nicholas Paisner

The U.S. biotech may succumb to Sanofi’s advances if both groups can agree on a payout tied to future performance. A contingent value right, worth some $1.5 bln, may leave investors wanting. But with Genzyme still struggling, this may be the best choice.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)